Experience with micronized progesterone used in combined hormone therapy in periand postmenopausal women
Objective. To evaluate the efficiency and safety of micronized progesterone as part of combined menopausal hormone therapy (MHT) in peri- and postmenopausal women. Subject and methods. Two groups of peri- and postmenopausal patients with climacteric syndrome receiving intermittent and continuous combined MHT regimens in accordance with the climacteric phase were examined. Results. The choice of a transdermal or intravaginal administration route for the hormonal components of MHT was substantiated in terms of a somatic disease in women and the efficiency and safety of these therapy regimens were evaluated. Conclusion. Prajisun used as part of different therapy regimens in women with varying degrees of climacteric syndrome shows good tolerability, effective endometrial control, and a low frequency of adverse reactions and it may be a drug of choice as a progestagenic component of combined MHT.